Klaria and PharmaMar initiate collaboration with a one-year study to develop a clinical development candidate of a PharmaMar compound formulated in Klaria’s Alginate Film technology
Klaria Pharma Holding AB (Nasdaq Stockholm: KLAR) announces that the company has signed an agreement with the Spanish biopharmaceutical company Pharma Mar (MSE:PHM), with the aim of performing a feasibility study for the purpose of developing an Alginate Film formulation of a PharmaMar compound. In the event of a positive outcome for this formulation development, the parties intend to negotiate a license agreement which will grant PharmaMar the global rights to the product.Klaria expanding collaboration based business model This collaboration with PharmaMar is the third research and